News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InSite Vision (ISV) Awarded Therapeutic Discovery Project Grant for ISV-502 and ISV-303 Clinical Development


11/4/2010 8:57:40 AM

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV), a company developing novel ophthalmic therapeutics, today announced that it will receive $489,000 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program. The grant was awarded in recognition of two clinical-stage programs, ISV-502, a product candidate being developed for the treatment of blepharitis, and ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES